A Phase 3 trial of SB 9225 (inarigivir + tenofovir disoproxil fumarate)

Trial Profile

A Phase 3 trial of SB 9225 (inarigivir + tenofovir disoproxil fumarate)

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Inarigivir-soproxil/tenofovir-disoproxil-fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 New trial record
    • 20 Mar 2018 According to a Spring Bank Pharmaceuticals media release, this trial is anticipated to initiate in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top